BCL-2 immunohistochemistry: understanding the result

The test is performed on a biopsy or other tissue sample. It shows which cells contain detectable protein and where staining appears within the sample; it does not, on its own, name a cancer or determine treatment.

A pathologist assesses the staining pattern, its intensity, the types of cells stained, and the appearance and arrangement of those cells under the microscope. Normal cells within the sample may also stain and can help with interpretation.

A positive result means BCL-2 protein was detected in the described cells. It is not the same as finding a BCL2 gene change, and positivity can occur in more than one benign or malignant process. The final pathology diagnosis may combine morphology, other stains, flow cytometry, and molecular or chromosome tests.

Read the BCL-2 line together with the final diagnosis and comment section, rather than interpreting the word positive in isolation. Check whether the report describes a specific cell population and whether additional testing is pending.

Your treating clinician can explain whether the stain supports the suspected diagnosis or mainly helps exclude alternatives. If the sample was small or the findings conflict, the care team may request more tissue, additional stains, or review by a specialist pathologist.

The staining result itself is not an emergency. Contact the team that performed the biopsy promptly if the sampling site develops increasing redness, swelling, drainage, worsening pain, or bleeding that does not stop with firm pressure.

Seek urgent care for severe trouble breathing, fainting, confusion, chest pain, or heavy bleeding. These warning signs require assessment because of the symptoms themselves, regardless of the BCL-2 result.

Ask which cells stained for BCL-2, how the pattern compares with the other markers, whether the diagnosis is final, and whether any molecular test is still pending. You can also ask how the complete pathology findings affect the next clinical decision.